1-9 of 9
Clare Spooner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ran Reshef, Constance Lau, Hil Hsu, Brett Doble, Clare Spooner, Anik R Patel, Liana Nikolaenko
Journal: Blood
Blood (2024) 144 (Supplement 1): 7775.
https://doi.org/10.1182/blood-2024-200288
Published: 2024
Journal Articles

Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Strouse, Umar Farooq, Roni Shouval, Anusha Vallurupalli, Amy Moskop, Caron A. Jacobson, Frederick Locke, John H. Baird, Paolo Strati, Dilan A. Patel, Saurabh Dahiya, Michael T. Hemmer, Brad Du, Clare Spooner, Jenny J. Kim, Debbie L. Mirjah, Zhen-Huan Hu, Marcelo C. Pasquini, Yi Lin
Journal: Blood
Blood (2024) 144 (Supplement 1): 609.
https://doi.org/10.1182/blood-2024-207976
Published: 2024
Journal Articles

Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients with Relapsed/Refractory Large B-Cell Lymphoma

David B. Miklos, Wike Tong, Eric Kim, Brandon Kerr, Morgan Neuwirth, Laura Alquist, Clare Spooner
Journal: Blood
Blood (2024) 144 (Supplement 1): 3477.
https://doi.org/10.1182/blood-2024-198267
Published: 2024
Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Clinical Trials & Observations
Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Armin Ghobadi, Sairah Ahmed, David B. Miklos, Miguel-Angel Perales, Javier Munoz, Warren B. Fingrut, Martina Pennisi, Jordan Gauthier, Mazyar Shadman, Lohith Gowda, Abu-Sayeef Mirza, Muhammad Bilal Abid, Sanghee Hong, Navneet S. Majhail, Mohamed A. Kharfan-Dabaja, Arushi Khurana, Talha Badar, Yi Lin, N. Nora Bennani, Megan M. Herr, Zhen-Huan Hu, Hai-Lin Wang, Anjani Baer, Elande Baro, Harry Miao, Clare Spooner, Hairong Xu, Marcelo C. Pasquini
Journal: Blood
Blood (2024) 143 (26): 2722–2734.
https://doi.org/10.1182/blood.2023023447
Published: 2024
Includes: Supplemental data
Journal Articles

Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1

Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Clare Spooner, Jenny J. Kim, Harry Miao, Allen Xiaodong Xue, Yan Zheng, Frederick L. Locke
Journal: Blood
Blood (2023) 142 (Supplement 1): 4864.
https://doi.org/10.1182/blood-2023-174288
Published: 2023
Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Matthew A. Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Harry Miao, Shilpa Shahani, Anik R. Patel, Clare Spooner, Christine Fu, Hairong Xu, Marcelo C Pasquini
Journal: Blood
Blood (2022) 140 (Supplement 1): 1852–1855.
https://doi.org/10.1182/blood-2022-162421
Published: 2022
Journal Articles

Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis

Javier Muñoz, Zhen-Huan Hu, Steve Kanters, Eve H. Limbrick-Oldfield, Harry Miao, Clare Spooner, Hairong Xu, Robin Sanderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4627–4629.
https://doi.org/10.1182/blood-2022-162582
Published: 2022
Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini
Journal: Blood
Blood (2022) 140 (Supplement 1): 7512–7515.
https://doi.org/10.1182/blood-2022-155603
Published: 2022
Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Caron Jacobson, Frederick L. Locke, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick Stiff, Ian W. Flinn, Umar Farooq, Andre H. Goy, Javier Muñoz, Tanya Siddiqi, Rhine R. Shen, Adrian Bot, Jinghui Dong, Kanwarjit Singh, Clare Spooner, Roshan Karalliyadda, Jenny J. Kim, Yan Zheng, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1764.
https://doi.org/10.1182/blood-2021-148078
Published: 2021